Stay updated on AbbVie Press Releases
Sign up to get notified when there's something new on the AbbVie Press Releases page.
![Latest website image capture](/pages/_next/image?url=https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fvp-files-ore%2Fresources%2F12months%2FNHdS1V9MeNW32ZfD9z3G48ZUH3k.uncropped.jpg&w=3840&q=75)
Latest updates to the AbbVie Press Releases page
- Check3 days agoChange DetectedAbbVie has added new video content highlighting employee experiences with migraine and the emotional impact of chronic lymphocytic leukemia (CLL), while removing information about the upcoming Migraine Career Catalyst Award contest and various tweets and news updates.SummaryDifference42%
- Check10 days agoChange DetectedAbbVie has awarded scholarships to 45 U.S. students with chronic immune-mediated diseases and introduced a new skin hydration product, while the deadline for the AbbVie Migraine Career Catalyst Award contest is approaching.SummaryDifference100%
- Check17 days agoChange DetectedThe European Commission has granted a second indication approval for TEPKINLY® (epcoritamab) for treating adults with relapsed/refractory follicular lymphoma, marking a significant development in blood cancer treatment.SummaryDifference63%
- Check24 days agoChange DetectedThe AbbVie Migraine Career Catalyst Award™ contest is nearing its entry deadline, with one month left to participate, while a previous post about ulcerative colitis has been removed.SummaryDifference16%
- Check32 days agoChange DetectedAbbVie has completed the acquisition of Cerevel Therapeutics as of August 1, 2024, marking a significant development in their portfolio, while the previous report on their second-quarter financial results from July 25, 2024, has been removed.SummaryDifference66%
- Check39 days agoChange DetectedOn July 30, 2024, Allergan Aesthetics is celebrating the Second Annual JUVÉDERM® Day, highlighting their commitment to accelerating the development of medicines and improving care for patients with inflammatory bowel disease (IBD).SummaryDifference68%
Stay in the know with updates to AbbVie Press Releases
Enter your email address, and we'll notify you when there's something new on the AbbVie Press Releases page.